Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IIH-Advance tirzepatide trial in active idiopathic intracranial hypertension
ISRCTN22446424Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in idiopathic intracranial hypertension (IIH) (2 arms), sponsored by University of Birmingham. Primary endpoint: Resolution of papilloedema. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on ISRCTN22446424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN22446424.